Skip to main content
. 2020 Nov 6;12:11333–11340. doi: 10.2147/CMAR.S279096

Table 2.

Comparison of Short-Term and Long-Term Effects Between Two Groups

Groups No (Case) Intracranial Progression Rate (%) Median IPFS (Months) Median OS (Months)
Combination therapy group 76 19.7 11.9 21.0
Target drug group 72 33.3 10.2 16.7
Χ2 value 4.210 4.249 4.107
P value 0.040 0.039 0.043